|Mr. Steven A. Kriegsman||Chairman & CEO||1.01M||N/A||1942|
|Mr. John Y. Caloz||CFO, Treasurer & Sr. VP||500k||N/A||1952|
|Molly Carey Poarch||Global & U.S. Head of Corp. Communications||N/A||N/A||N/A|
|Ms. Molly Painter||Pres of USA and Head of Launch & Commercial Operations||N/A||N/A||N/A|
|Terri Stevens||Chief Bus. Officer||N/A||N/A||N/A|
|Dr. Felix Kratz Ph.D.||Sr. VP, Drug Devel.||N/A||N/A||1963|
CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
CytRx Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.